Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Reaffirms FY 2013 Guidance-Conference Call


Thursday, 25 Apr 2013 07:00am EDT 

AstraZeneca PLC announced that for fiscal 2013, it continues to expect a mid to high single-digit decline in revenue in constant currency and core earnings per share (EPS) to decline at a rate significantly higher than the decline in revenue. The Company reported revenue of $27.973 billion and EPS of $6.41 in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $26.397 billion and EPS of $5.83 for fiscal 2013.